首页> 外文OA文献 >Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

【2h】

Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

机译：一，以药代动力学为基础的剂量I期，确定每天连续定量（CI）白消安（BU）与固定剂量氟达拉滨（FLU）静脉连续输注（CI）白消安（BU）的最大耐受剂量（MTD）为每天7603 Umol * Min / Hr的AUC异基因干细胞移植后血液系统恶性肿瘤患者（PTS）的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wood W.A.; Walko C.M.; Rao K.V.; Whitley J.; Moore D.T.; Gabriel D.A.; Serody J.S.; Coghill J.M.; Shea T.C.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. [J] . Tran HT, Madden T, Petropoulos D, Bone marrow transplantation . 2000,第5期

机译：个体化大剂量口服白消安：正在接受同种异体干细胞移植的晚期血液恶性肿瘤儿科患者的前瞻性剂量调整。
2. Romidepsin (Rom) in Combination with Fludarabine (Flu) and Busulfan (Bu) Conditioning Followed by Rom Maintenance in Patients with T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT): Early Results of a Phase I/II Trial [J] . Jonathan E. Brammer, Ben C. Valdez, Richard E. Champlin, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：Romidepsin（ROM）与Fludarabine（Flu）和Busulfan（Bu）调节组合，然后在接受同种异体干细胞移植（Allo-SCT）的T细胞恶性肿瘤患者中进行ROM维护：I / II期试验的早期结果
3. Romidepsin (Rom) in Combination with Fludarabine (Flu) and Busulfan (Bu) Conditioning Followed by Rom Maintenance in Patients with T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant (Allo-SCT): Early Results of a Phase I/II Trial [J] . Jonathan E. Brammer, Ben C. Valdez, Richard E. Champlin, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：Romidepsin（ROM）与Fludarabine（Flu）和Busulfan（Bu）调节组合，然后在接受同种异体干细胞移植（Allo-SCT）的T细胞恶性肿瘤患者中进行ROM维护：I / II期试验的早期结果
4. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease [O] . PETER H. O’DONNELL, ANDREW S. ARTZ, SAMIR D. UNDEVIA, -1

机译：I阶段I与氟胺和Alemtuzumab的剂量升级的套管为单位造血干细胞移植调理：高剂量降低和晚期正弦梗阻综合征/静脉闭塞病的发生
5. 229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults [O] . Waxman I., Bhatia M., Milone M., 2008

机译：229：接受同种异体造血干细胞移植（AlloHSCT）的减低强度调节（RIC）方案的儿童，每天两次静脉（IV）白消安（Bu）x 4天是安全且耐受性良好的，但可显着提高Bu清除率（CL）和减少的曲线下面积（AUC）和半衰期（t1 / 2）与成人静脉内两次每日剂量药代动力学（PK）相比

著录项

引文网络

相似文献

相关主题

期刊订阅